Aurora Partners with Script Assist to Provide Better Access to UK Medical Cannabis

Rhea-AI Summary

Aurora Cannabis Inc. partners with Script Assist to empower UK patients with high-quality medical cannabis products and guidance. The partnership aims to enhance the UK medical cannabis landscape by providing access to premium products and valuable information through an innovative technology platform.

Insights

Market Research Analyst

The partnership between Aurora Cannabis Inc. and Script Assist represents a strategic move to penetrate the UK medical cannabis market more effectively. By leveraging Script Assist's platform, Aurora aims to enhance the patient experience by simplifying the prescription process and ensuring the availability of high-quality medical cannabis products. This initiative could potentially increase Aurora's market share and brand visibility in the UK.

From a market research perspective, the integration of technology in healthcare, especially platforms that connect patients with doctors, is a growing trend. This partnership aligns with the consumer demand for streamlined healthcare services and could set a precedent for digital transformations within the cannabis industry. The introduction of new products, such as the high THC and balanced THC/CBD options, caters to diverse patient needs, indicating Aurora's commitment to product differentiation and innovation.

Medical Research Analyst

The availability of high-quality, EU GMP-certified medical cannabis products through an accessible platform could have significant implications for patient outcomes in the UK. Good Manufacturing Practice (GMP) certification ensures that products are consistently produced and controlled to quality standards. It is crucial for medical cannabis, as quality and consistency are vital for patient safety and efficacy of treatment.

Furthermore, the 'Find a Doctor' feature could enhance the overall treatment landscape by facilitating the connection between patients and specialist doctors. This could lead to better-informed prescriptions and more personalized care. However, the long-term impact on patient health and the overall medical cannabis market will depend on the uptake of the platform, the effectiveness of the products and the quality of care provided by the prescribing doctors.

Financial Analyst

The announcement of Aurora Cannabis Inc.'s partnership with Script Assist could be seen as an investment in the company's future growth within the UK market. As Aurora expands its product offerings and streamlines access for patients, investors will be looking at the potential for increased sales and market penetration as key indicators of success. The move to provide EU GMP-certified products could also be viewed favorably by investors who are concerned with regulatory compliance and product quality.

While this partnership may drive revenue growth for Aurora in the UK, the impact on the company's overall financial health will need to be evaluated over time. Factors such as the cost of establishing and maintaining the partnership, marketing expenses and the competitive response from other market players will influence the financial outcomes. It will be important to monitor Aurora's financial reports in subsequent quarters to assess the partnership's contribution to the bottom line.

                                                                                                        NASDAQ | TSX: ACB

Partnership will empower UK patients with valuable information and guidance critical to a successful cannabis experience  

EDMONTON, AB, Feb. 28, 2024 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, today announced the partnership of Aurora Medicine UK Ltd with Script Assist, a cutting-edge medical cannabis prescription platform in the UK.

Designed to support UK patients on their journey of well-being, the Script Assist platform provides access to high quality medication through their portal. Script Assist will make available an extensive range of medical cannabis products from Aurora's leading portfolio of products. Starting in March three newly launched, high-quality hang-dried and hand-processed flower products from Aurora's EU GMP facilities in Canada will also become available on www.scriptassist.co.uk: Pedanios 26/1 EHD-CA (Cultivar: Electric Honey Dew) and Pedanios 28/1 CMK-CA (Cultivar: Chemango Kush) with a high THC content, as well as Pedanios 10/10 EQI-CA (Cultivar: Equiposa) with balanced THC/CBD content.

"Together with our new partner, we are committed to further improve the UK medical cannabis landscape by providing patients with access to premium, high-quality products through Script Assist's innovative technology solution," said Trisha Cassidy, Managing Director, Aurora UK & Ireland. "We believe it is necessary and critical to expand not only access to products, but also provide valuable information to guide patients through their medical cannabis journey. We are proud to be a trusted partner for their health," said Cassidy.

Within the platform, Script Assist is launching 'Find a Doctor', an easy-to-use app, which seamlessly connects patients with specialist prescribing doctors. The full range of Aurora's medical cannabis products will be available for patients through prescription by all private doctors and clinics using the platform, transforming the UK medical cannabis prescription journey.

About Script Assist 

Script Assist revolutionises the medical cannabis prescription process in the UK by enabling private doctors and clinics to provide an easy-to-use app to their patients, including features such as transparent payment and tracking alongside live inventory levels for seamless in-app repeat requests. With the launch of its "Find a Doctor" feature, for the first time UK patients can effortlessly choose their own private doctor and then access fully streamlined medical cannabis prescriptions. The app can be accessed via the platform www.scriptassist.co.uk.

About Aurora Cannabis

Aurora is opening the world to cannabis, serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Through its subsidiary Aurora Europe GmbH, Aurora supplies high-quality medical cannabis products to patients in the German, Polish and UK markets among others, making it one of the largest authorized importers and distributors in the European Union & UK. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched. Aurora carries out its operations in compliance with all applicable laws in the countries in which it operates. Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the Nasdaq and TSX under the symbol "ACB" and is a constituent of the S&P/TSX Composite Index.

Forward Looking Information

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include statements regarding the Company's partnership with Script Assist, including with respect to the availability of the Company's medical cannabis products for patients in the UK and the Company's continued commitment to further improve the UK medical cannabis landscape.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 14, 2023 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-partners-with-script-assist-to-provide-better-access-to-uk-medical-cannabis-302074109.html

SOURCE Aurora Cannabis Inc.

FAQ

What is the partnership about?

The partnership between Aurora Cannabis Inc. and Script Assist aims to empower UK patients with high-quality medical cannabis products and guidance.

What products will be available on Script Assist's platform?

Aurora's EU GMP facilities in Canada will provide three newly launched, high-quality hang-dried and hand-processed flower products on www.scriptassist.co.uk.

Who is the Managing Director of Aurora UK & Ireland?

Trisha Cassidy is the Managing Director of Aurora UK & Ireland.

What new feature is Script Assist launching within the platform?

Script Assist is launching 'Find a Doctor', an app that connects patients with specialist prescribing doctors.

How will patients access Aurora's medical cannabis products?

Patients can access Aurora's medical cannabis products through prescription by all private doctors and clinics using the Script Assist platform.